C4Diagnostics SAS

C4Diagnostics SAS is a French company focused on developing rapid diagnostic tools for infectious diseases, particularly aiming to enhance the detection of Aspergillus from air samples through innovative technology. Founded in 2017 and headquartered in Marseille, France, C4Diagnostics specializes in diagnostic tools for infectious diseases. The company has successfully completed three deals, with its latest funding round occurring on March 5, 2020, raising EUR 2. 27 mn from investors including CAAP Creation and Région Sud Investissement.

The current company valuation stands at EUR 10. 224 mn. C4Diagnostics specializes in developing rapid diagnostic tools for infectious diseases, emphasizing the detection of Aspergillus from air samples. Utilizing their proprietary Click-chemistry technology, they offer an in vitro diagnostic (IVD) test that provides reliable detection of Aspergillus within six hours.

Their market includes hospitals, laboratories, and environmental monitoring sectors primarily in Europe and North America, improving the efficiency of infectious disease diagnostics. In its most recent fiscal year, C4Diagnostics reported revenue of EUR 2,815,852. 90 and an EBITDA of EUR 227,607. 70, generated through B2B transactions and partnerships with healthcare providers and distributors.

Looking ahead, C4Diagnostics plans to expand its product line with new innovations in diagnostic testing, targeting a launch within the next 18 months. The company also aims to penetrate new markets in Asia and South America by 2022. The EUR 2. 27 mn raised in March 2020 will support these initiatives, helping to enhance their product development and market outreach.